General information
  • Disease category Other (BASEC)
  • Recruitment status recruitment not started yet (BASEC/ICTRP)
  • Trial sites
    Zurich
    (BASEC)
  • Contact Sybille Schwendener sybille.schwendener@zzm.uzh.ch (BASEC)
  • Data Source(s) BASEC: Import from 24.04.2026 ICTRP: N/A
  • Last update 24.04.2026 09:10
HumRes68090 | SNCTP000006889 | BASEC2025-02383

Intake of Probiotic with Streptococcus salivarius K12 Bacteria: Colonization of the Oral Cavity, Effects on Oral Flora and Oral Inflammatory Markers

  • Disease category Other (BASEC)
  • Recruitment status recruitment not started yet (BASEC/ICTRP)
  • Trial sites
    Zurich
    (BASEC)
  • Contact Sybille Schwendener sybille.schwendener@zzm.uzh.ch (BASEC)
  • Data Source(s) BASEC: Import from 24.04.2026 ICTRP: N/A
  • Last update 24.04.2026 09:10

Summary description of the study

Probiotics contain live microorganisms that should provide health benefits. The lozenges BIOTICS-O from Burgerstein contain live Streptococcus salivarius BLIS® K12 bacteria and are intended to optimally support the oral and throat flora. This pilot study investigates the effect of BIOTICS-O. 12 healthy participants will consume one lozenge daily for 4 weeks. Saliva and dental plaque samples will be examined before, during, and after the treatment phase. The main question is whether the probiotic bacteria Streptococcus salivarius BLIS® K12 can colonize the oral cavity and whether they can influence the composition of the oral flora. Additionally, the saliva of the participants will also be tested for inflammatory markers to measure any potential effect on the immune system. This pilot study will assess the impact of BIOTICS-O on oral health.

(BASEC)

Intervention under investigation

Dietary Supplement Burgerstein BIOTICS-O

(BASEC)

Disease under investigation

Oral Health

(BASEC)

Criteria for participation in trial
- Healthy adults (> 18 years) - No untreated caries or active periodontal disease (BASEC)

Exclusion criteria
- Intake of anti-inflammatory medications, antimicrobial substances, and probiotics in the last 4 weeks (BASEC)

Trial sites

Zurich

(BASEC)

not available

Sponsor

Klinik für Zahnerhaltung und Präventivzahnmedizin, Zentrum für Zahnmedizin, Zürich

(BASEC)

Contact

Contact Person Switzerland

Sybille Schwendener

+41 44 634 33 76

sybille.schwendener@zzm.uzh.ch

Universität Zürich Zentrum für Zahnmedizin Klinik für Zahnerhaltung und Präventivzahnmedizin

(BASEC)

Scientific Information

not available

Name of the authorising ethics committee (for multicentre studies, only the lead committee)

Ethics Committee Zurich

(BASEC)

Date of authorisation

24.04.2026

(BASEC)


ICTRP Trial ID
not available

Official title (approved by ethics committee)
Administration of oral probiotic Streptococcus salivarius K12: oral colonization, impact on oral microbiome and inflammatory markers (BASEC)

Academic title
not available

Public title
not available

Disease under investigation
not available

Intervention under investigation
not available

Type of trial
not available

Trial design
not available

Inclusion/Exclusion criteria
not available

not available

Primary and secondary end points
not available

not available

Registration date
not available

Incorporation of the first participant
not available

Secondary sponsors
not available

Additional contacts
not available

Secondary trial IDs
not available

Results-Individual Participant Data (IPD)
not available

Further information on the trial
not available

Results of the trial

Results summary

not available

Link to the results in the primary register

not available